SciBase Reports Significant Growth in Q4 2025 Amidst Challenges in Market Dynamics SciBase's interim report highlights a 45% increase in net sales for Q4 2025 despite facing operational challenges, marking a critical moment in its growth trajectory.

SciBase Reports Significant Growth in Q4 2025 Amidst Challenges in Market Dynamics #Sweden #Stockholm #dermatology #Nevisense #SciBase

Nevisense's New EIS Technology Revolutionizes Skin Barrier Impairment Assessment A recent study validates Nevisense's Electrical Impedance Spectroscopy as a crucial tool for evaluating skin barrier health, enhancing traditional assessments.

Nevisense's New EIS Technology Revolutionizes Skin Barrier Impairment Assessment #Sweden #Stockholm #Nevisense #SciBase #EIS

How Nevisense is Transforming Melanoma Detection in the US Clinicians' Practice Discover how US clinicians are leveraging Nevisense to enhance melanoma detection rates and improve diagnostic accuracy through real-world applications.

How Nevisense is Transforming Melanoma Detection in the US Clinicians' Practice #USA #New_York #Nevisense #SciBase #melanoma

SciBase's FDA Approval Allows Expanded Nevisense Usage for Healthcare Professionals SciBase receives FDA approval to extend Nevisense labelling, enabling healthcare practitioners beyond dermatologists to perform crucial skin assessments.

SciBase's FDA Approval Allows Expanded Nevisense Usage for Healthcare Professionals #Sweden #FDA_Approval #Stockholm #Nevisense #SciBase

SciBase’s Nevisense Technology Spearheads Melanoma Detection in NCCN Guidelines SciBase's innovative Nevisense system is now officially recognized in the NCCN guidelines, marking a significant step in melanoma detection and diagnosis.

SciBase’s Nevisense Technology Spearheads Melanoma Detection in NCCN Guidelines #Sweden #Stockholm #Nevisense #SciBase #melanoma

SciBase Announces Key Adjustments to Warrants of Series TO 2 Post-Rights Issue SciBase has recalculated the terms of its series TO 2 warrants following a recent rights issue, updating crucial trading details and subscription options for shareholders.

SciBase Announces Key Adjustments to Warrants of Series TO 2 Post-Rights Issue #Sweden #Stockholm #Warrants #SciBase #Rights_Issue

SciBase Reports Successful Completion of Rights Issue and Set-off Share Allocation SciBase announces the successful completion of its rights issue, with a significant uptake and a new share allocation strategy for investors holding TO 2 warrants.

SciBase Reports Successful Completion of Rights Issue and Set-off Share Allocation #Sweden #Stockholm #SciBase #Rights_Issue #TO_2_Warrants

SciBase Holding AB Adjusts Publication Date for 2025 Year-End Report SciBase Holding AB has announced a delay in the publication of its year-end report for 2025, now scheduled for March 13, 2026, to align with a rights issue.

SciBase Holding AB Adjusts Publication Date for 2025 Year-End Report #Sweden #Stockholm #Nevisense #SciBase #financial_report

SciBase Shows Strong Commitment in Ongoing Rights Issue Amidst Shareholder Support SciBase Holding AB is advancing its rights issue, backed by significant commitments from major shareholders, enhancing support for its innovative skin diagnostic solutions.

SciBase Shows Strong Commitment in Ongoing Rights Issue Amidst Shareholder Support #Sweden #Stockholm #Nevisense #SciBase #Life_Science

SciBase Announces Significant Rights Issue to Raise Capital for Future Innovations SciBase Holding AB has published a detailed information document about its ongoing rights issue aimed at raising approximately SEK 83 million. Explore key details about the initiative.

SciBase Announces Significant Rights Issue to Raise Capital for Future Innovations #Sweden #Stockholm #Nevisense #SciBase #Bergh_Securities

SciBase Reports Successful Repurchase of TO 2 Warrants, Boosting Company Shares SciBase Holding AB announces the successful outcome of its offer to repurchase outstanding TO 2 warrants, resulting in a significant issuance of new shares, enhancing its market position.

SciBase Reports Successful Repurchase of TO 2 Warrants, Boosting Company Shares #Sweden #Stockholm #Warrants #SciBase #TO_2

SciBase Announces Rights Issue to Raise Approximately 83 Million SEK for US Operations SciBase Holding AB's Board has approved a rights issue of approximately SEK 83 million, focusing on US market expansion. Subscribe from Jan 12-26.

SciBase Announces Rights Issue to Raise Approximately 83 Million SEK for US Operations #Sweden #Stockholm #dermatology #Nevisense #SciBase

SciBase Strengthens Its Intellectual Property with A New European Patent for Skin Barrier Analysis SciBase Holding AB announces the granting of a European patent aimed at analyzing the epithelial skin barrier, showcasing its commitment to advancement in dermatological technology.

SciBase Strengthens Its Intellectual Property with A New European Patent for Skin Barrier Analysis #Sweden #Stockholm #SciBase #European_Patent #epithelial_skin_barrier

SciBase Announces Offer to Repurchase Outstanding Warrants of Series TO 2 SciBase is set to repurchase all outstanding warrants of series TO 2. The offer, which begins December 8, 2025, aims to streamline its financial structure.

SciBase Announces Offer to Repurchase Outstanding Warrants of Series TO 2 #Sweden #Stockholm #Nevisense #SciBase #TO_2_Offer

SciBase Holds Extraordinary General Meeting to Authorize Share Issuance and Enhance Strategic Flexibility SciBase Holding AB recently conducted an extraordinary general meeting, approving a proposal for share issuance and emphasizing strategic growth. This decision positions the company for future advancements in dermatological technology.

SciBase Holds Extraordinary General Meeting to Authorize Share Issuance and Enhance Strategic Flexibility #Sweden #Stockholm #dermatology #Nevisense #SciBase

SciBase Board Approves Warrant Repurchase and Rights Issue Strategy to Boost Capital Structure The SciBase Board of Directors has approved a plan to repurchase outstanding warrants while also initiating a rights issue targeting SEK 83 million to strengthen its capital structure.

SciBase Board Approves Warrant Repurchase and Rights Issue Strategy to Boost Capital Structure #Sweden #Stockholm #SciBase #Rights_Issue #TO_2_Offer

SciBase Interim Report Shows Growth Amidst Financial Losses in Q3 2025 SciBase's Q3 2025 interim report highlights a 23% increase in net sales, yet reveals financial challenges with rising losses. Insights into their market performance and future plans are discussed.

SciBase Interim Report Shows Growth Amidst Financial Losses in Q3 2025 #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

SciBase and Castle Biosciences Unveil Expanded Collaboration and Loan Agreement SciBase and Castle Biosciences have strengthened their partnership with an expanded collaboration and a SEK 20 million loan agreement to enhance diagnostic solutions.

SciBase and Castle Biosciences Unveil Expanded Collaboration and Loan Agreement #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

SciBase's Nevisense: A Revolutionary Tool in Atopic Dermatitis Skin Barrier Research Discover how SciBase's Nevisense is advancing skin barrier research in atopic dermatitis, enhancing diagnostic methods and treatment monitoring.

SciBase's Nevisense: A Revolutionary Tool in Atopic Dermatitis Skin Barrier Research #Sweden #Stockholm #Atopic_Dermatitis #Nevisense #SciBase

SciBase Partners with Castle Biosciences for Clinical Study in Dermatology Innovations SciBase announces its collaboration with Castle Biosciences, receiving an initial order for a clinical study focused on atopic dermatitis.

SciBase Partners with Castle Biosciences for Clinical Study in Dermatology Innovations #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

Major Stakeholders Increase Their Investment in SciBase for Future Growth SciBase, a leader in AI for dermatology, sees major stakeholders enhance their investment through new share purchases, anticipating significant growth.

Major Stakeholders Increase Their Investment in SciBase for Future Growth #Sweden #Investment #Stockholm #dermatology #SciBase

New Study Highlights Importance of Reader Studies in Dermatology for Nevisense Validation A recent study confirms the critical role of reader studies in validating SciBase's Nevisense, enhancing real-world diagnostic accuracy in dermatology.

New Study Highlights Importance of Reader Studies in Dermatology for Nevisense Validation #Sweden #Stockholm #Nevisense #SciBase #Reader_Studies

SciBase Reports Significant Growth in Q2 2025 Interim Results Amid Challenges SciBase's Q2 2025 interim report showcases a remarkable 32% increase in net sales, alongside notable advancements in product offerings and collaborations amid ongoing challenges.

SciBase Reports Significant Growth in Q2 2025 Interim Results Amid Challenges #Sweden #Stockholm #dermatology #Nevisense #SciBase

SciBase Finalizes Directed Share Issue to Castle Biosciences - An Investment of SEK 19 Million SciBase Holding AB has concluded a SEK 19 million directed share issue to Castle Biosciences, enhancing its financial position and market strategy.

SciBase Finalizes Directed Share Issue to Castle Biosciences - An Investment of SEK 19 Million #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

SciBase Unveils Exciting Nevisense Pilot Program at Renowned Florida University for Skin Cancer Detection SciBase is launching a significant pilot program for Nevisense's skin cancer detection technology at a top university in Southeast Florida.

SciBase Unveils Exciting Nevisense Pilot Program at Renowned Florida University for Skin Cancer Detection #United_States #Nevisense #SciBase #Skin_Cancer #Southeast_Florida

Palm Beach Dermatology Group Partners with SciBase for Melanoma Detection Innovation SciBase collaborates with Palm Beach Dermatology to enhance melanoma detection with innovative Nevisense technology, aiming to improve patient outcomes.

Palm Beach Dermatology Group Partners with SciBase for Melanoma Detection Innovation #United_States #Palm_Beach #dermatology #Nevisense #SciBase

Just visited SciBase their tech is changing the game in early skin cancer detection, especially melanoma. Non-invasive, data-driven and incredibly smart.
🔬 Learn more: scibase.com
#SkinHealth #MelanomaAwareness #InnovationInSkincare #SciBase

SciBase Completes Successful Directed Share Issue Raising SEK 11 Million On June 30, 2025, SciBase announced the successful completion of its directed share issue, raising SEK 11 million to expand its operations.

SciBase Completes Successful Directed Share Issue Raising SEK 11 Million #Sweden #Stockholm #Nevisense #SciBase #share_issue

SciBase Announces New Share Issue to Raise Funds for Growth in U.S. Market SciBase Holding AB has approved a directed share issue of SEK 11 million to support market expansion and product development. The funds will facilitate U.S. operations and enhance diagnostic capabilities.

SciBase Announces New Share Issue to Raise Funds for Growth in U.S. Market #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

Highlights from the 2025 Annual General Meeting of SciBase Holding AB The 2025 Annual General Meeting of SciBase Holding AB addressed key financial resolutions and board appointments, showcasing the company's strategic direction.

Highlights from the 2025 Annual General Meeting of SciBase Holding AB #Sweden #Stockholm #Nevisense #SciBase #Annual_General_Meeting